Side-by-side · Research reference
PT-141vsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedReviewed13/41 cited
BHuman-MechanisticDraft12/40 cited
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
PT-141
Thymalin
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
—
—
Origin
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
PT-141
Thymalin
Standard dose
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
5–10 mg / day IM × 5–10 daysKhavinson 2002
Frequency
PRN, max 8 doses / month
Once daily during cycle
Lower / starter dose
1 mg (off-label)
2.5 mg / day
Evidence basis
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Russian clinical + in vitroKhavinson 2002
Duration
PRN; reassess if no benefit after 8 doses
5–10 day cycles, 1–2× per year
Reconstitution
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Saline or bacteriostatic water
Timing
≥45 min before sexual activity
Morning preferred
04Side Effects & Safety
Parameter
PT-141
Thymalin
Flushing
Common, transient
—
Injection site reaction
Erythema, mild pain
Mild erythema at IM site
Headache
Common
—
Hyperpigmentation (focal)
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
—
Hypertension (transient)
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
—
Pregnancy / OB
Contraindicated
Avoid
Cardiovascular disease
Use caution; transient BP rise
—
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Long-term safety
—
Limited Western data
Absolute Contraindications
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
PT-141
Thymalin
1. Reconstitution
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Injection site
SQ — abdomen or thigh.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
Morning preferred during cycle.
4. Storage
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Needle
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
23–25G, 25–38 mm IM needle.
06Stack Synergy
PT-141
— no documented stacks
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation